Put the full cost on the page.
A headline price leaves questions open. Write down the terms before comparing the total.
A cash-price reference, with its limits
A vial is a small bottle; the KwikPen is a prefilled injection pen holding medicine for several injections. A single-dose pen holds medicine for just one injection.
On September 26, 2026, the maker’s posted cash prices for tirzepatide (Zepbound) vials or KwikPen ranged from $299 to $699 per 28-day supply.
In those vial and KwikPen offers, the products normally priced at $499 or $699 had a $449 refill price if each refill was completed within 45 days of receiving the previous supply.
After that deadline, the regular $499 or $699 price applied, depending on the strength, or how much medicine each injection contains.
The terms reviewed September 26, 2026, set December 31, 2026, as the date these offers are due to end.
These prices apply to vials and the multi-dose KwikPen, not the single-dose pen.
Ask which product name is on the box and which regular price applies to it. Ask what happens to the price if a refill is delayed.
These dated medicine prices do not tell you what your own care will cost. Ask about the proposed form and the entire bill.
The government cash-price site also lists offers; its September 26, 2026, headlines are starting prices, not prices for every strength or month.
As of that date, those cash payments do not reduce the deductible, the amount a plan requires before it starts paying.
They also do not count toward its out-of-pocket cap, the yearly limit on covered costs you pay.
A separate Medicare route has limits
As checked September 26, 2026, ordinary Medicare drug coverage excludes medicines used only for weight loss.
GLP-1 is a body chemical message that helps control appetite and blood sugar. The program below takes its name from medicines that act on it.
The temporary Medicare GLP-1 Bridge offers eligible adults certain weight medicines for a $50 monthly patient payment. The program opens July 1, 2026, and its last day is December 31, 2027.
For tirzepatide (Zepbound), that program includes the KwikPen only, excluding vials and single-dose pens.
The $50 payment does not count toward Medicare’s yearly limit on covered costs you pay. For people on low incomes, the program does not provide added help to cover that payment.
Eligibility rules, checked September 26, 2026, depend on age, weight history, health conditions, plan type and past drug claims.
Type 2 diabetes, which affects blood sugar, and moderate to severe obstructive sleep apnea, meaning repeated blocked breathing during sleep, go through regular Medicare drug coverage rather than the Bridge.
Check the route with both your prescriber and your plan.
Being eligible for regular coverage does not settle what your own plan will pay.
Make your cost question list
Fill in what you have been told. Leave an answer blank when it is still unclear. No health history or contact details are needed.